TY - JOUR
T1 - Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma
AU - Pilozzi, Emanuela
AU - Pulford, Karen
AU - Jones, Margaret
AU - Müller-Hermelink, Hans Konrad
AU - Falini, Brunangelo
AU - Ralfkiaer, Elisabeth
AU - Pileri, Stefano
AU - Pezzella, Francesco
AU - De Wolf-Peeters, Christine
AU - Arber, Daniel
AU - Stein, Harald
AU - Mason, David
AU - Gatter, Kevin
PY - 1998/10
Y1 - 1998/10
N2 - Acute lymphoblastic leukaemia/lymphoma is a malignant disorder derived from the clonal proliferation of lymphoid precursor cells. Whether the tumour cells are of B- or T-cell type is an important criterion for prognosis which has not been available previously to pathologists, due to the lack of a reliable early B-cell marker functioning on routinely processed material. This has changed with the production of monoclonal antibodies against the B- cell signalling molecule CD79a. CD79a is expressed on normal and neoplastic B cells from the early stages of B-cell maturation and has been considered to be B-cell-specific. Currently available antibodies against CD79a, in particular JCB117, allow the identification of B cells, and hence B lymphoblastic disease, in paraffin-embedded material. In this study, the expression of CD79a (JCB117) and CD3 has been investigated in 149 cases of T and 68 cases of B lymphoblastic leukaemia/lymphoma. For the first time, co- expression of CD79a (JCB117) and CD3 is reported in 10 per cent of cases of T lymphoblastic leukaemia/lymphoma. This finding raises questions about the co- expression of T- and B-cell markers in the development of lymphocytes, benign as well as malignant, and alerts pathologists to a potential problem in diagnosis.
AB - Acute lymphoblastic leukaemia/lymphoma is a malignant disorder derived from the clonal proliferation of lymphoid precursor cells. Whether the tumour cells are of B- or T-cell type is an important criterion for prognosis which has not been available previously to pathologists, due to the lack of a reliable early B-cell marker functioning on routinely processed material. This has changed with the production of monoclonal antibodies against the B- cell signalling molecule CD79a. CD79a is expressed on normal and neoplastic B cells from the early stages of B-cell maturation and has been considered to be B-cell-specific. Currently available antibodies against CD79a, in particular JCB117, allow the identification of B cells, and hence B lymphoblastic disease, in paraffin-embedded material. In this study, the expression of CD79a (JCB117) and CD3 has been investigated in 149 cases of T and 68 cases of B lymphoblastic leukaemia/lymphoma. For the first time, co- expression of CD79a (JCB117) and CD3 is reported in 10 per cent of cases of T lymphoblastic leukaemia/lymphoma. This finding raises questions about the co- expression of T- and B-cell markers in the development of lymphocytes, benign as well as malignant, and alerts pathologists to a potential problem in diagnosis.
KW - CD3
KW - CD79a
KW - Lymphoblastic lymphoma
UR - http://www.scopus.com/inward/record.url?scp=0031720541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031720541&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1096-9896(1998100)186:2<140::AID-PATH149>3.0.CO;2-Y
DO - 10.1002/(SICI)1096-9896(1998100)186:2<140::AID-PATH149>3.0.CO;2-Y
M3 - Article
C2 - 9924428
AN - SCOPUS:0031720541
VL - 186
SP - 140
EP - 143
JO - Journal of Pathology
JF - Journal of Pathology
SN - 0022-3417
IS - 2
ER -